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AbstrAct
Breast cancer screening has led to a dramatic increase in the detection of pre-
invasive breast lesions. While mastectomy is almost guaranteed to treat the disease, 
more conservative approaches could be as effective if patients can be stratified based 
on risk of co-existing or recurrent invasive disease. 
Here we use a range of biomarkers to interrogate and classify purely non-invasive 
lesions (PNL) and those with co-existing invasive breast cancer (CEIN). Apart from 
Ductal Carcinoma in situ (DCIS), relative homogeneity is observed. DCIS contained a 
greater spread of molecular subtypes. Interestingly, high expression of p-mTOR was 
observed in all PNL with lower expression in DCIS and invasive carcinoma while the 
opposite expression pattern was observed for TOP2A. 
Comparing PNL with CEIN, we have identified p53 and Ki67 as predictors of CEIN 
with a combined PPV and NPV of 90.48% and 43.3% respectively. Furthermore, HER2 
expression showed the best concordance between DCIS and its invasive counterpart.
We propose that these biomarkers can be used to improve the management 
of patients with pre-invasive breast lesions following further validation and clinical 
trials. p53 and Ki67 could be used to stratify patients into low and high-risk groups 
for co-existing disease. Knowledge of expression of more actionable targets such as 
HER2 or TOP2A can be used to design chemoprevention or neo-adjuvant strategies. 
Increased knowledge of the molecular profile of pre-invasive lesions can only serve 
to enhance our understanding of the disease and, in the era of personalised medicine, 
bring us closer to improving breast cancer care.
IntroductIon
A variety of non-invasive lesions are encountered in 
breast tissue whether derived from resection specimens or 
core biopsy material. An increased understanding of the 
prognosis associated with the prototypical pre-invasive 
lesion ductal carcinoma in situ (DCIS) is required to both 
adequately manage and avoid overtreatment [1]. Predictive 
and prognostic biomarkers are required; not only for low-
risk patients but also in high grade DCIS as its patient-
specific propensity to progress to invasion is imprecisely 
represented by clinicopathologic characteristics and 
standard biomarkers [2]. 
Breast screening programmes have increased 
not only the frequency of in situ disease detection but 
also others such as columnar cell lesions (CCL). The 
proportion of UK screening detected cancers classified 
as in situ was 20% during 2013/2014 [3]. During the 
same period the proportion of biopsied lesions classified 
as benign was 9%. The detection of lesions, for example 
CCL, may be clinically important: whilst they are not 
in themselves aggressive they are frequently associated 
with particular invasive carcinoma types such as low 
grade infiltrating ductal and classic lobular carcinoma [4, 
5]. Therefore how should these non-invasive lesions be 
managed when present in apparent isolation and how can 
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they be further characterised?
While simple mastectomy will undoubtedly 
effectively treat in situ carcinoma and other non-invasive 
lesions, more conservative resection with or without 
radiotherapy may achieve similar success [6, 7]. In 
essence, the addition of radiotherapy or systemic therapy 
to surgical intervention is insurance against the minority 
of patients who will subsequently present with invasive 
cancer [8]. A recent retrospective study from Narod et 
al. analysed over 100,000 cases of DCIS with extensive 
follow-up data [9]. They found that aggressive treatment 
did not reduce the number of breast cancer associated 
deaths highlighting the need for novel treatment strategies. 
They also demonstrate that occurrence of invasive cancer 
after DCIS substantially increases the risk of cancer-
related death. Given the fact that the characteristics of 
DCIS can predict those of subsequent invasive disease, 
more robust characterisation of DCIS can inform 
preventative strategies. Currently, no reliable diagnostic 
approach exists to identify lesions likely to progress or 
to become invasive. Therefore other parameters, not only 
to treat but also to help decide the risk of recurrence or 
progression are required. 
We sought to determine the molecular characteristics 
of lesions associated with invasive carcinoma in 
comparison with lesions existing in a pure form (purely 
non-invasive lesions, or PNL in this manuscript) in terms 
of established biomarkers and potential druggable targets 
[10]. By measuring possible differences in expression, we 
sought to infer likely co-existence of invasive carcinoma 
(CEIN) in breast specimens thereby identifying markers of 
possible prognostic utility. We tested the hypothesis that 
alterations in biomarker expression would occur across 
lesions representative of a spectrum from morphologically 
normal, benign, in situ and invasive carcinoma.
results
The consort diagram and derivation of cases 
is summarised in Figure 1. Patient clinicopathologic 
information for CEIN lesions is presented in 
Supplementary Table 2. Median and modal ages of 
patients with PNLs were 50 and 53 respectively (range 
18-80 years). A total of 266 non-invasive lesions were 
available for analysis, following exclusion of cases 
missing blocks or if lesions cut out during sectioning and 
staining. The PNL group comprised 17 normal samples; 9 
apocrine metaplastic lesions; 28 CCL; 8 LCIS; 21 DCIS; 
9 others represented a range of infrequently encountered 
lesions. The CEIN group comprised 40 ‘normal’ 
samples (terminal ductulo-lobular units); 18 apocrine 
metaplastic lesions; 31 CCL; 18 LCIS; 60 DCIS; 7 others 
represented a range of infrequently encountered lesions 
(Supplementary Table 4). The following results pertain to 
normal, apocrine metaplasia (AM), CCL, LCIS, DCIS and 
invasive carcinoma.
expression of molecular subtypes according to 
lesion type
We assessed the frequency of molecular subtypes 
per lesion class. Fifty-seven examples of morphologically 
normal ductulo-lobular units were assessable of which 
98% displayed luminal expression. The single non-luminal 
example had a triple negative phenotype and was from the 
CEIN group. Ninety-six percent of luminal examples had 
a luminal A phenotype. Another CEIN case was classified 
as LBHN due to high Ki67 expression. Two cases could 
not be refined beyond luminal classification. The 24 
classifiable cases of AM were all of a triple negative 
phenotype.
Fifty-eight examples of CCL were assessable, all 
having a luminal phenotype. Ninety-two percent of these 
were of luminal A phenotype. The remaining examples 
were of LBHN phenotype and displayed morphologic 
features of FEA (flat epithelial atypia): namely, columnar 
cells with non-basally orientated rounded nuclei and mild 
atypia.
Of the twenty-six cases of LCIS, 80% were defined 
as luminal A and 20% as LBHN. All but one of these 
was CEIN related. One case could not be further defined. 
Eighty-four percent of the eighty examples of DCIS were 
of luminal phenotype. In this group of DCIS type lesions 
39% were luminal A, 21% LBHN, 24% LBHP, 6% HE and 
10% TN phenotype. DCIS from the CEIN group showed 
luminal phenotype in 81% of cases. The remaining cases 
contained all the TN phenotype tumours. In the PNL 
group, luminal phenotype was defined in 86% of cases.
Morphologic and molecular phenotypic features 
of dcIs
Given that DCIS, compared to the other lesion 
types studied, has the greatest potential for progression to 
invasion, although the rate at which this occurs is variable, 
we explored the relationship between morphologic 
appearances and molecular phenotype. Fewer than half of 
luminal DCIS cases (45%) had associated comedonecrosis 
whereas a greater proportion (77%) of non-luminal cases 
showed this feature. When limited to PNL, a 33% of cases 
displayed comedonecrosis whereas 55% of CEIN lesions 
demonstrated this.
All but one of the non-luminal DCIS examples were 
high grade (92%), the other being classed as intermediate 
grade. Luminal DCIS was dominated by high grade 
examples (52%) but contained a greater proportion of 
intermediate (31%) and low grades (16%). Within the PNL 
group, 43% of DCIS was high grade, 33% intermediate 
grade and 24% low grade. This is significantly different 
to CEIN DCIS where a greater proportion was high grade 
(65%) with fewer cases showing intermediate (25%) and 
low grade (10%) morphology (p-value 0.0034).
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Figure 1: consort diagram of study cohort
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expression of novel biomarkers
Having described the non-invasive case cohort 
in terms of molecular phenotype we then wished to 
characterise these cases in terms of more novel biomarker 
targets both singly (Figure 2) and within molecular 
subclasses (Supplementary Tables 5 and 6). TOP2A 
expression occurred in 36% of DCIS with expression 
occurring seldom or not at all in other lesions. The 
majority of cases expressing TOP2A were high grade 
(none were low grade) and usually associated with 
invasive carcinoma. 
EGFR expression was frequent in normal (39%) and 
apocrine metaplasia (50%), absent in CCL and present 
in LCIS (4%) and DCIS (13%). Expression was faint 
in benign lesions while DCIS and invasive carcinoma 
occasionally showed more intense expression. The 
majority of DCIS cases expressing EGFR were CEIN 
related (9 of the 10 positive cases had associated invasive 
carcinoma), mostly high grade or intermediate grade, 
and almost all with comedonecrosis. EGFR expression 
was relatively more frequent in non-luminal examples of 
DCIS. All of the normal examples with EGFR expression 
were LA phenotype.
Loss of IGF1R occurred most often in apocrine 
metaplasia (40%) followed by DCIS (11%). In the small 
number of DCIS cases with loss, the majority were high 
grade (88% or 100% when intermediate was included) 
and related to CEIN. Additionally, 75% of cases showing 
loss also demonstrated comedonecrosis. The few DCIS 
cases with complete loss were LBHP or TN while all AM 
examples were TN.
PTEN assessment was difficult in a number of 
cases, posing similar challenges in interpretation reported 
by other groups due to variations in intensity and the 
presence of both cytoplasmic and nuclear expression 
[11, 12]. PTEN loss occurred most frequently in LCIS 
(23%) but at similar rates in normal (19%), CCL (16%) 
and DCIS (20%): in all of these examples loss of PTEN 
was most frequent with CEIN lesions (Figure 3). A single 
PNL apocrine metaplastic focus demonstrated PTEN loss. 
In the DCIS PTEN loss group, 87% were high grade or 
intermediate grade. Comedonecrosis occurred in 47% 
of PTEN loss cases and 53% of PTEN retention cases. 
In DCIS, PTEN loss occurred in almost all molecular 
phenotypes.
Aside from apocrine metaplasia, the majority of 
lesions of each type expressed p-mTOR particularly 
in the PNL group. mTOR over-expression occurred in 
CCL (94%), FEA (95%) and LCIS (92%). 75% of DCIS 
expressed p-mTOR. Just over half of positive cases (53%) 
had associated comedonecrosis especially from the CEIN 
group. Thirty-nine percent of p-mTOR negative cases had 
comedonecrosis. p-mTOR over-expression occurred in all 
DCIS molecular phenotypes.
Figure 2: trends of expression of biomarkers within different lesion subtypes.
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differences in biomarker expression between 
matched dcIs and invasive carcinoma
The level of agreement between the molecular 
phenotype of DCIS and invasive carcinoma in specific 
cases was explored. Overall, by Cohen’s kappa coefficient, 
the degree of agreement was moderate (κ = 0.561; 95% 
confidence interval: 0.332 to 0.791). While the majority of 
cases showed broadly concordant luminal status molecular 
phenotypic expression between in situ and invasive 
disease, in ten cases were discordant. This increased to at 
least 21 when precise molecular phenotype was defined. 
Discordant cases are summarised in Supplementary Table 
3. 
The level of agreement, or lack of change, between 
individual biomarkers assessed in DCIS and in their 
invasive counterparts is shown in Table 1. The best 
concordance was demonstrated by HER2. Moderate 
concordance was found with TOP2A, EGFR, p53, ER 
and PR. The remainder showed fair to poor concordance. 
Apart from HER2, as the remaining biomarkers showed 
less concordance between DCIS and their invasive 
counterparts, we calculated the overlap of biomarker 
expressions in HER2 negative cases (Figure 3). The most 
often expressed biomarkers in the remaining cases were 
ER (82.6%) and TOP2A (28.4%): 17.4% of cases co-
expressed both biomarkers. This also demonstrates the 
complexity of biomarker expression within DCIS, which 
underlies the lack of clear therapeutic avenues.
In terms of biomarker relation to sample type, only 
p53 expression showed a significant relation (p = 0.0091) 
Figure 3: Venn diagram displaying the biomarker expression overlaps for Her2 negative dcIs cases. All values are 
percentages of cases. PTEN and IGF1R refer to expression loss. All other biomarkers refer to over-expression.
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with sample type, tending to be positive when DCIS was 
associated with a co-existent invasive carcinoma (Table 
2). Similarly, Ki67 tended (p = 0.060) to indicate high 
proliferation when DCIS was associated with invasive 
carcinoma compared to DCIS existing purely alone. The 
positive predictive value (PPV) and negative predictive 
values (NPV) for p53 alone in this situation were 89.19% 
and 37.21% respectively. Ki67 alone produced a PPV 
of 87.85% and NPV of 32.58%. However, assessing 
agreement of both biomarkers produced the best results 
with a PPV of 90.48% and NPV of 43.33%. Sensitivity and 
specificity were 53% and 87% respectively. Performing 
the analysis when assessing both or either biomarker 
positivity did not improve predictive values further; 
however, sensitivity and specificity were both 72% in this 
instance. Calculations of the relationship between sample 
type and luminal versus non-luminal status, DCIS grade 
and presence of comedonecrosis were not significant (data 
not shown).
dIscussIon
In this study, we investigated the molecular 
characteristics of lesions associated with invasive 
carcinoma (CEIN) versus purely non-invasive 
lesions (PNL) with the aim of identifying potential 
prognostic biomarkers as well as potential targets for 
chemoprevention. Apart from DCIS, pre-invasive 
lesions are a relatively homogenous group, dominated 
by a luminal phenotype. As may be expected from 
higher association with progression, DCIS is a much 
more heterogeneous group with a spectrum of molecular 
classifications and biomarker expression. This is in 
keeping with a recent publication, using multiple 
platforms to present a comprehensive molecular portrait, 
demonstrating multiple molecular subgroups within DCIS 
[13]. Of note, p-mTOR expression was high in most 
benign and pre-neoplastic lesions with reduced expression 
table 1: concordance between biomarker scores in dcIs and related invasive lesions
biomarker Kappa Interpretation
ER 0.581 moderate
PR 0.418 moderate
HER2 0.839 very good
Ki67 0.298 fair
p53 NE vs EP/EN 0.336 fair
p53 EN vs NE vs EP 0.457* moderate
TOP2A 0.423 moderate
EGFR 0.522 moderate
IGF1R 0.387 fair
PTEN 0.339 fair
p-mTOR 0.153 poor
Kappa Coefficient interpretation index: 0-0.20 = Poor, 0.21-0.40 = Fair, 0.41-0.60= Moderate, 0.61-0.80 = Substantial, 
0.81-1 = Almost Perfect.
*weighted kappa = 0.540.
table 2: Fisher’s exact test contingency table analysis of biomarker expression between Pnl and ceIn
normal AM ccc/FeA lcIs dcIs
er NS NS NS NS NS
Pr NS NS NS NS NS
Her2 NS NS NS NS NS
Ki67 NS NS NS NS 0.06*
P53 NS NS NS NS 0.0091**
toP2A NS NS NS NS 0.1063
eGFr NS NS NS NS NS
IGF1r NS NS NS NS NS
Pten NS NS NS NS NS
p-mtor NS NS NS NS NS
Oncotarget43250www.impactjournals.com/oncotarget
in DCIS and invasive carcinoma. TOP2A expression was 
associated with DCIS, usually high grade and associated 
with invasive carcinoma. We demonstrate that p53 and 
Ki67 expression may predict the association of DCIS 
with invasive carcinoma and that HER2 shows the best 
concordance between in situ and invasive lesions.
The importance of better describing risk in DCIS 
relates to it not being the inevitable harbinger of invasive 
carcinoma, not only because a spectrum of lesion 
aggressiveness exists but as natural lesion evolution may 
span several decades. Consequently, most consider DCIS 
a non-obligate precursor to invasive breast carcinoma. 
However, at least one study has shown that untreated 
DCIS is at increased risk of progression regardless of 
grade of in situ disease although lower grade lesions may 
progress more slowly [14]. In our study we found no 
relationship between DCIS grade or comedonecrosis and 
association with invasion.
The emphasis in breast cancer management is 
increasingly towards earlier invasive lesions and pre-
invasive stages of disease. Early detection provides 
opportunities but also new challenges in correctly 
determining the significance of lesions to avoid 
overtreatment [15]. Preventative approaches are preferable 
to managing invasive carcinoma, not only because of 
reduced risk of distant spread but also the avoidance 
or reduction of treatment resistance and possibility for 
less drastic intervention. Strategies for prevention are 
facilitated by increasingly sensitive lesion detection and 
availability of screening. This might also facilitate active 
surveillance of specific non-invasive lesions at low risk of 
progression and use of p53 and Ki67, as described here, 
may help realise these aims [16]. 
In cases where only DCIS is detected, the inevitable 
question is can the use of biomarkers influence patient 
care? Biomarkers such as p53 and Ki67 would be used to 
stratify based on likelihood of presence of an undetected 
co-existing invasive carcinoma. It would be inferred 
that women at low risk of CEIN could be offered more 
conservative surgery with or without radiotherapy based 
on additional clinical parameters. On the other hand, 
high-risk patients would be offered full mastectomy and/
or radiotherapy and/or additional systemic treatment as 
determined by biomarker status and additional clinical 
information. In addition, as IHC-based biomarker 
assessment can be carried out on core biopsy material, this 
mean that these parameters can be taken into account at 
the time of diagnosis rather than waiting for the excision 
biopsy when surgery has already been performed.
Other studies have examined the utility of 
biomarkers in predicting subsequent invasive carcinoma. 
Kerlikowske et al. studied the characteristics of patients 
with DCIS who later developed invasive carcinoma [17]. 
In the 170 patients with progression, a combination of 
Ki67 positivity with positivity for p16 and COX2 in the 
initial in situ lesion was significantly associated with 
subsequent invasion. Similar findings showing increased 
risk of subsequent in situ, but not invasive recurrence 
were reported by Rakovitch et al. using a combination 
of HER2 and Ki67 positivity [18]. Ki67 positivity in our 
study was associated but not significantly (p = 0.06) with 
greater likelihood of presence of invasion. A small study 
addressing rare cases of distant metastases following 
an initial diagnosis and treatment for DCIS may allude 
to occult invasive foci or particularly aggressive disease 
[19]. In this series 74% of patients with distant recurrences 
had DCIS with necrosis while almost two thirds were 
ER negative hinting towards an aggressive non-luminal 
phenotype.
Of the standard-of-care predictive biomarkers and 
additional potential actionable targets, HER2 showed 
the best concordance between in situ and invasive 
carcinoma in individual cases. This implies that DCIS 
surrounding invasive carcinoma is most similar to its 
HER2 invasive counterpart. Consequently, if a patient is 
identified as being at higher risk of CEIN, and the DCIS 
is HER2 positive, use of HER2 targeted therapies would 
be of benefit in not only targeting the DCIS but also any 
associated undetected invasive carcinoma. Conversely, 
treatment of HER2 positive invasive carcinoma will also 
be likely to target co-existing DCIS. When HER2 positive 
DCIS was excluded the most often expressed biomarkers 
in the remaining cases were ER (82.6%) and TOP2A 
(28.4%) with 17.4% of cases co-expressing both. TOP2A 
was associated with higher grade DCIS and a tendency 
for concurrent invasive disease similar to other reported 
findings [20, 21]. Hormone receptor and anthracycline 
based therapies may be indicated in these cases [22]. 
Few trials exist to test the hypothesis that non-
surgical intervention may be optimal in at least a subgroup 
of patients with DCIS. Most published work evaluates 
protocols to predict the risk of tumour recurrence (in 
situ and invasive) following excision [23]. However, 
the cancer and leukaemia group B (CALGB) 40903 
study (NCT01439711) aims to determine what subsets 
of ER positive DCIS might be amenable to neoadjuvant 
endocrine therapy with the proviso that all patients will 
eventually have surgical excision. Such intervention may 
cause complete lesion regression or reduce lesional size 
to an extent where more localised resection is possible. 
A randomised phase I/II trial (NCT00555152), yet to 
report, is assessing the effects of neoadjuvant lapatinib 
(a tyrosine kinase inhibitor causing dual inhibition of 
HER2 and EGFR) in DCIS by measuring changes in 
Ki67 index at the time of surgical excision. DeCensi 
et al. previously reported on the effects of lapatinib in 
HER2 positive invasive carcinoma and surrounding 
lesions, including DCIS, in 60 women. They found non-
significant (p = 0.067) reductions in the mean Ki67 index 
in patients treated neoadjuvantly with lapatinib [24]. The 
neoadjuvant effects of trastuzumab on DCIS have been 
assessed by Kuerer et al. [25]. From an initial 69 eligible 
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patients, 24 had in situ lesions with HER2 overexpression 
and 12 of these received the drug. The single pre-operative 
dose did not produce any significant pathologic, anti-
proliferative or anti-apoptotic effects as assessed on 
resection specimens. Notably, 5 patients showed evidence 
of invasive disease in resection specimens. Another trial 
is expected to report on the benefit of trastuzumab with 
radiotherapy given to patients with HER2 positive DCIS 
following lumpectomy [26]. This is an important option 
in hormone receptor negative DCIS and estimates suggest 
that approximately 40 - 50% of pure DCIS may be HER2 
positive [27, 28]. Our findings would suggest that targeted 
biomarker informed therapies could be used in the neo-
adjuvant setting to potentially negate the need for surgery 
completely. Furthermore, given the increasing emphasis 
on knowledge of tumour heterogeneity and its potential 
influence on multiple aspects of tumour biology including 
progression, spread and treatment response, molecular 
characterisation of co-existing DCIS may aid in clinical 
management decisions in the future.
In summary, the benign and early neoplastic 
lesions described herein display homogeneity in their 
molecular profiles. The greatest diversity of biomarker 
expression occurs at the in situ carcinoma phase of non-
invasive lesions. Defining the molecular profile of in situ 
disease may help in deciphering the likelihood of related 
invasive disease, the risk or recurrence and hence inform 
management decisions. Enhancing our understanding of 
both similarities and differences between non-invasive 
and invasive lesions may aid in predicting the response 
to treatment.
MAterIAls And MetHods
Case identification
Ethical approval was obtained and tissue acquired 
for this research through the Northern Ireland Biobank 
(NIB ref: 12-00017). Patients with PNLs had no previous 
breast cancer and no cancer developed since diagnosed, 
while patients with invasive carcinoma all underwent 
surgery and adjuvant chemotherapy. For PNLs, specimens 
were identified through our hospital laboratory database 
during the 2008 to 2011 period. Non-invasive diagnostic 
terms were compiled into a search limited to complete 
mastectomies and wide local excisions: core biopsies 
were excluded. The slides from all available cases were 
reviewed to confirm diagnostic coding and the most 
representative blocks selected for biomarker analysis. 
Only lesions of sufficient size or extent unlikely to cut out 
during sectioning were selected for further analysis. CEIN 
lesions were derived from a previous study originating 
from the same institutional archival material and following 
slide review, representative blocks were selected for 
further analysis [29, 30]. All of the material was reviewed 
by 2 breast cancer pathologists (DPB and TFL).
lesion diagnoses
Classification and grading of DCIS was performed 
according to UK national guidance [31]. Grading was 
defined as low, intermediate or high. The presence of 
comedonecrosis was recorded. Columnar cell lesions 
were diagnosed and categorised with the nomenclature 
suggested by Schnitt et al. [32, 33]. All other lesions 
were assessed according to standard diagnostic criteria 
(Supplementary Table 1).
Immunohistochemical analyses
Immunohistochemical analysis for ER, PR, HER2, 
Ki67, p53, TOP2A, EGFR, IGF1R, PTEN and p-mTOR 
was performed using automated immunostainers. The 
specific clones, internally optimised antibody conditions 
(dilution and pre-treatment) and automated platform 
used are presented in Supplementary Table 1. The 
expression of each biomarker was assessed in the tumour 
or normal epithelial component of each region of interest 
under investigation. The majority of the biomarkers 
were subjectively scored by semi-quantitative analysis 
according to standards previously set out in the literature 
and discussed in a recent review [10]. Briefly, twelve 
whole tissue sections for IHC were cut at 4 microns on a 
rotary microtome, dried at 37oC overnight and then used 
for IHC assays on Ventana DISCOVERY® XT or Leica 
BOND-MAX™ automated immunostainers. Analyses 
were limited to lesions with at least 5 examples. These 
biomarkers were used because they are a) key for the 
classification of breast cancer; and/or b) are potential 
companion diagnostics for drugs tested in early phase 
clinical trials in invasive breast cancer.
Molecular subtype assignation was performed 
using a cohort of markers (ER, PR, HER2, Ki67) in 
accordance with recent recommendations [34]. The 5 
molecular subtypes were defined as luminal A (ER+, 
PgR+, HER2- Ki67 low), luminal B HER2 negative (ER+, 
HER2- and at least one of Ki67 high or PgR), luminal B 
HER2 positive (ER+, HER2+), HER2 enriched (HER2+, 
ER- and PgR-) and triple-negative (ER-, PgR-, HER2-). 
Cases were also dichotomised, where possible, as luminal 
or non-luminal when a full cohort of biomarkers was 
unavailable. A number of representative images are shown 
in Supplementary Figure1.
statistical analyses
Statistical analyses were performed using GraphPad 
PRISM and R (https://CRAN.R-project.org) with Venn 
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diagrams constructed using the R package Vennerable 
(http://R-Forge.R-project.org/projects/vennerable). 
Measures of agreement for biomarker interpretation 
between DCIS and invasive carcinoma were expressed 
by calculating kappa values [35]. Quantification of the 
relationship between biomarkers and their expression in 
particular sample types was performed using contingency 
tables and analysis by Fisher’s exact test or chi-square 
test as appropriate. P-values were not multiple hypothesis 
corrected. Following this, for significant results, biomarker 
positive and negative predictive values were calculated. 
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